Literature DB >> 24354797

Expression of insulin-like growth factor-1 receptor in metastatic uveal melanoma and implications for potential autocrine and paracrine tumor cell growth.

Makoto Yoshida1, Senthamil Selvan, Peter A McCue, Tiziana DeAngelis, Renato Baserga, Ami Fujii, Hallgeir Rui, Michael J Mastrangelo, Takami Sato.   

Abstract

We investigated the importance of the insulin-like growth factor-1 receptor (IGF-1R) in hepatic metastases of uveal melanoma. The expression pattern of IGF-1R in archival tissue samples of hepatic metastasis from 24 patients was analyzed by immunohistochemistry. All the samples of hepatic metastases stained positive for IGF-1R. To investigate the biological role of IGF-1R on the growth of metastatic uveal melanoma, a long-term cell line obtained from a hepatic metastasis (TJU-UM001) was evaluated. TJU-UM001 expressed cell surface IGF-1R (>90%) and proliferated in response to exogenous and endogenous insulin-like growth factor-1 (IGF-1). Correlatively, anti-IGF-1R antibody completely blocked IGF-1-induced growth of TJU-UM001 cells. IGF-1 preferentially induced phosphorylation of Akt (S473) in quiescent TJU-UM001 cells, and this was blocked by anti-IGF-1R antibody. This study suggests that autocrine and paracrine mechanisms underlie IGF-1-induced growth of metastatic uveal melanoma and underscore the potential benefit of IGF-1 or IGF-1R antagonism in treatment for metastatic uveal melanoma.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  autocrine; hepatic metastasis; insulin-like growth factor-1; insulin-like growth factor-1 receptor; paracrine; uveal melanoma

Mesh:

Substances:

Year:  2014        PMID: 24354797     DOI: 10.1111/pcmr.12206

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN: 1755-1471            Impact factor:   4.693


  19 in total

1.  Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma.

Authors:  Hanyin Cheng; Vivian Chua; Connie Liao; Timothy J Purwin; Mizue Terai; Ken Kageyama; Michael A Davies; Takami Sato; Andrew E Aplin
Journal:  Mol Cancer Ther       Date:  2017-01-30       Impact factor: 6.261

2.  Metabolic Adaptations to MEK and CDK4/6 Cotargeting in Uveal Melanoma.

Authors:  Jessica L F Teh; Timothy J Purwin; Anna Han; Vivian Chua; Prem Patel; Usman Baqai; Connie Liao; Nelisa Bechtel; Takami Sato; Michael A Davies; Julio Aguirre-Ghiso; Andrew E Aplin
Journal:  Mol Cancer Ther       Date:  2020-05-19       Impact factor: 6.261

3.  Novel Treatments of Uveal Melanoma Identified with a Synthetic Lethal CRISPR/Cas9 Screen.

Authors:  Kseniya Glinkina; Arwin Groenewoud; Amina F A S Teunisse; B Ewa Snaar-Jagalska; Aart G Jochemsen
Journal:  Cancers (Basel)       Date:  2022-06-29       Impact factor: 6.575

4.  Establishment and Characterization of Orthotopic Mouse Models for Human Uveal Melanoma Hepatic Colonization.

Authors:  Shinji Ozaki; Raja Vuyyuru; Ken Kageyama; Mizue Terai; Masahiro Ohara; Hanyin Cheng; Tim Manser; Michael J Mastrangelo; Andrew E Aplin; Takami Sato
Journal:  Am J Pathol       Date:  2015-11-25       Impact factor: 4.307

5.  Male pattern baldness and risk of incident skin cancer in a cohort of men.

Authors:  Wen-Qing Li; Eunyoung Cho; Jiali Han; Martin A Weinstock; Abrar A Qureshi
Journal:  Int J Cancer       Date:  2016-09-08       Impact factor: 7.396

6.  Paracrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal Melanoma.

Authors:  Hanyin Cheng; Mizue Terai; Ken Kageyama; Shinji Ozaki; Peter A McCue; Takami Sato; Andrew E Aplin
Journal:  Cancer Res       Date:  2015-05-07       Impact factor: 12.701

7.  The transcription factor RUNX2 regulates receptor tyrosine kinase expression in melanoma.

Authors:  Rajeev K Boregowda; Daniel J Medina; Elke Markert; Michael A Bryan; Wenjin Chen; Suzie Chen; Anna Rabkin; Michael J Vido; Samuel I Gunderson; Marina Chekmareva; David J Foran; Ahmed Lasfar; James S Goydos; Karine A Cohen-Solal
Journal:  Oncotarget       Date:  2016-05-17

8.  Arterial Blood, Rather Than Venous Blood, is a Better Source for Circulating Melanoma Cells.

Authors:  Mizue Terai; Zhaomei Mu; David J Eschelman; Carin F Gonsalves; Ken Kageyama; Inna Chervoneva; Marlana Orloff; Ryan Weight; Michael J Mastrangelo; Massimo Cristofanilli; Takami Sato
Journal:  EBioMedicine       Date:  2015-09-18       Impact factor: 8.143

9.  Targeting growth hormone receptor in human melanoma cells attenuates tumor progression and epithelial mesenchymal transition via suppression of multiple oncogenic pathways.

Authors:  Reetobrata Basu; Shiyong Wu; John J Kopchick
Journal:  Oncotarget       Date:  2017-03-28

Review 10.  Metabolic Alterations and Therapeutic Opportunities in Rare Forms of Melanoma.

Authors:  Anna Han; Zachary T Schug; Andrew E Aplin
Journal:  Trends Cancer       Date:  2021-06-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.